Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association

BJPsych Bulletin

Volumn 41, Issue 4, 2017, Pages 211-216

  Sarkar, Siddharth ^a   Gupta, Nitin ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; DIFFERENTIAL DIAGNOSIS; DRUG RECHALLENGE; HUMAN; MEDICATION THERAPY MANAGEMENT; MENTAL HEALTH; NEUROLEPTIC MALIGNANT SYNDROME; RISK FACTOR;

EID: 85028499122     PISSN: 20564694     EISSN: 20564708     Source Type: Journal    
DOI: 10.1192/pb.bp.l16.053736     Document Type: Article

References (48)

1. Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 2012;201:52-6.
2. Langan J, Martin D, Shajahan P, Smith DJ. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry 2012;12:214.
3. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J | Psychiatry 2007;164:870-6.
4. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011;72:1222-8.
5. Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 2005;28:197-204.
6. Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocritical Care 2016;24:97-103.
7. Nakamura M, Yasunaga H, Miyata H, Shimada T, Horiguchi H, Matsuda S. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry 2012;73:427-30.
8. Tarsy D, Baldessarini RJ, Tarazi Fl. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.
9. Belvederi Murri M, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs RD 2015;15:45-62.
10. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477-92.
11. Pope HG, Cole JO, Choras PT, Fulwiler CE. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986;174:493-5.
12. Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44:548-56.
13. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2070;121:4-10.
14. Buckley PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001;50:912-24.
15. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
16. Owens DC. How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia. Adv Psychiatr Treat 2008;14:17-28.
17. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70.
18. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993;24:161-76.
19. Amore M, Zazzeri N, Berardi D. Atypical neuroleptic malignant syndrome associated with clozapine treatment. Neuropsychobiology 1997;35:197-9.
20. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999;33:623-30.
21. Licup N, Baumrucker SJ. Olanzapine for nausea and vomiting. Am J Hosp Palliat Care 2010;27:432-4.
22. Musshoff F, Doberentz E, Madea B. Lethal neuroleptic malignant syndrome due to amisulpride. Forensic Sci Med Pathol 2013;9:218-20.
23. Tsai JH, Yang P, Yen JY, Chen CC, Yang MJ. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy 2005;25:1156-9.
24. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20:389-409.
25. Detweiler MB, Sullivan K, Sharma TR, Kim KY, Detweiler JG. Case reports of neuroleptic malignant syndrome in context of quetiapine use. Psychiatr Q 2013;84:523-41.
26. Chen Y-T, Su K-P, Chang JP-C. Early detection and management of atypical neuroleptic malignant syndrome secondary to aripiprazole. Schizophr Res 2011;132:97-8.
27. Tseng PT, Chang YC, Chang CH, Wang HY, Cheng YS, Wu CK, et al. Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. Int J Psychiatry Med 2015;49:35-43.
28. Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Therapeut 2004;26:1105-8.
29. Ozen ME, Yumru M, Savas HA, Cansel N, Herken H. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry 2007;8:42-4.
30. Mantas C, Kalabokis G, Goulia P, Tourlakopoulos A, Hyphantis T, Mavreas V. Possible neuroleptic malignant syndrome during paliperidone administration: a case report. J Clin Psychopharmacol 2010;30:89-91.
31. Teng PR, Lane HY. Emergence of neuroleptic maligriant syndrome while switching between risperidone and paliperidone. J Neuropsychiatry Clin Neurosci 2011;23:E16.
32. Hsu W-C, Lin S-T, Chen C-C, Tsang H-Y, Huang M-F. A self-limiting case of atypical neuroleptic malignant syndrome associated with zotepine. J Clin Psychopharmacology 2011;31:667-9.
33. Guanci N, Aggarwal R, Schleifer S. Atypical neuroleptic malignant syndrome associated with iloperidone administration. Psychosomatics 2012;53:603-5.
34. Ohoyama K, Tanii H, Motomura E, Konishi Y, Nakagawa M, Matsumoto T, et al. Neuroleptic malignant syndrome induced by blonanserin. J Neuropsychiatry Clin Neurosci 2011;23:E13.
35. Patel MK, Brunetti L. Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient. Am J Health Syst Pharm 2010;67:1254-9.
36. Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithiuminduced neuroleptic malignant syndrome. Ann Pharmacother 2006;40:139-42.
37. Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand 2014;130:52-60.
38. Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE Jr. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008;28:530-5..
39. Caroff SN, Mann SC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000;30:314-21.
40. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-45.
41. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986;143:1587-90.
42. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf 2009;4:84-93.
43. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001;72:325-36.
44. Frucht SJ. Treatment of movement disorder emergencies. Neurotherapeutics 2014;11:208-12.
45. Anbalagan E, Ithman M, Lauriello J. Rechallenging clozapine after neuroleptic malignant syndrome. Psychiatr Q 2014;85:345-8.
46. Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012;134:180-6.
47. Mendhekar DN, Jiloha RC, Mehndiratta MM, War L. Challenge with atypical antipsychotic drugs in risperidone induced neuroleptic malignant syndrome: a case report. In J Psychiatry 2002;44:387-90.
48. Ross C. Successful clozapine rechallenge following clozapine-induced neuroleptic malignant syndrome. Ment Health Clin 2015;5:88-90.